Results 21 to 30 of about 33,638 (296)
Blood Advances, 2020 Abstract Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM) and was identified to be selective for JAK2 relative to other JAK family ...
Ruben A. Mesa +5 more
openaire +3 more sources
Murine Models of Myelofibrosis [PDF]
Cancers, 2020 Myelofibrosis (MF) is subtype of myeloproliferative neoplasm (MPN) characterized by a relatively poor prognosis in patients. Understanding the factors that drive MF pathogenesis is crucial to identifying novel therapeutic approaches with the potential to improve patient care.
Steven W. Lane +5 more
openaire +4 more sources
Journal of Clinical Apheresis, Volume 37, Issue 6, Page 544-552, December 2022., 2022 Abstract Background Thrombocytosis is a presenting and progressive clinical feature found in multiple disease states. It is characterized by high platelet (PLT) counts (>450 × 109/L) and can lead to thrombohemorrhagic events. Thrombocytapheresis or platelet depletion (PLTD) can be performed in acutely symptomatic patients suffering from thrombocytosis ...
Pamela Lopert +13 more
wiley +1 more source
Gaucher Disease and Myelofibrosis: A Combined Disease or a Misdiagnosis? [PDF]
, 2018 Background: Gaucher disease (GD) and primary myelofibrosis (PMF) share similar clinical and laboratory features, such as cytopenia, hepatosplenomegaly, and marrow fibrosis, often resulting in a misdiagnosis.
Cardarelli, L +5 more
core +1 more source
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
, 2019 Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
Haematologica, 2010 Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer +2 more
doaj +1 more source
Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]
, 2019 Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela +1 more
core +1 more source
Advances in myelofibrosis: a clinical case approach
Haematologica, 2013 Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas +5 more
doaj +1 more source
Osteochondrosis lesions of the lateral trochlear ridge of the distal femur in four ponies [PDF]
, 2011 Lesions of the lateral trochlear ridge (LTR) of the distal femur were investigated in four pony or pony cross horses. The animals were all geldings and were six to 15 months of age.
Henson, F.M.D. +3 more
core +1 more source
Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. [PDF]
PLoS ONE, 2014 Identifying a distinct gene signature for myelofibrosis may yield novel information of the genes, which are responsible for progression of essential thrombocythemia and polycythemia vera towards myelofibrosis.
Hans Carl Hasselbalch +7 more
doaj +1 more source